Exact Mass: 495.3321566
Exact Mass Matches: 495.3321566
Found 351 metabolites which its exact mass value is equals to given mass value 495.3321566,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
Mibefradil
C - Cardiovascular system > C08 - Calcium channel blockers > C08C - Selective calcium channel blockers with mainly vascular effects D004791 - Enzyme Inhibitors > D065607 - Cytochrome P-450 Enzyme Inhibitors > D065609 - Cytochrome P-450 CYP1A2 Inhibitors C78274 - Agent Affecting Cardiovascular System > C270 - Antihypertensive Agent > C333 - Calcium Channel Blocker D002317 - Cardiovascular Agents > D002121 - Calcium Channel Blockers D002317 - Cardiovascular Agents > D000959 - Antihypertensive Agents D002317 - Cardiovascular Agents > D014665 - Vasodilator Agents D000077264 - Calcium-Regulating Hormones and Agents D049990 - Membrane Transport Modulators C93038 - Cation Channel Blocker
JI-20B
C20H41N5O9 (495.2904136000001)
D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D005839 - Gentamicins
(2R,3R,4R,5R)-2-[(1S,2S,3R,4S,6R)-4,6-diamino-3-[(2R,3R,4R,5S,6R)-3-amino-6-[(1S)-1-aminoethyl]-4,5-dihydroxy-tetrahydropyran-2-yl]oxy-2-hydroxy-cyclohexoxy]-5-methyl-4-(methylamino)tetrahydropyran-3,5-diol
C20H41N5O9 (495.2904136000001)
LysoPC(16:0/0:0)
C24H50NO7P (495.33247200000005)
LysoPC(16:0) is a lysophospholipid (LyP). It is a monoglycerophospholipid in which a phosphorylcholine moiety occupies a glycerol substitution site. Lysophosphatidylcholines can have different combinations of fatty acids of varying lengths and saturation attached at the C-1 (sn-1) position. Fatty acids containing 16, 18 and 20 carbons are the most common. LysoPC(16:0), in particular, consists of one chain of palmitic acid at the C-1 position. The palmitic acid moiety is derived from fish oils, milk fats, vegetable oils and animal fats. Lysophosphatidylcholine is found in small amounts in most tissues. It is formed by hydrolysis of phosphatidylcholine by the enzyme phospholipase A2, as part of the de-acylation/re-acylation cycle that controls its overall molecular species composition. It can also be formed inadvertently during extraction of lipids from tissues if the phospholipase is activated by careless handling. In blood plasma significant amounts of lysophosphatidylcholine are formed by a specific enzyme system, lecithin:cholesterol acyltransferase (LCAT), which is secreted from the liver. The enzyme catalyzes the transfer of the fatty acids of position sn-2 of phosphatidylcholine to the free cholesterol in plasma, with formation of cholesterol esters and lysophosphatidylcholine. Lysophospholipids have a role in lipid signaling by acting on lysophospholipid receptors (LPL-R). LPL-Rs are members of the G protein-coupled receptor family of integral membrane proteins. [HMDB] LysoPC(16:0) is a lysophospholipid (LyP). It is a monoglycerophospholipid in which a phosphorylcholine moiety occupies a glycerol substitution site. Lysophosphatidylcholines can have different combinations of fatty acids of varying lengths and saturation attached at the C-1 (sn-1) position. Fatty acids containing 16, 18 and 20 carbons are the most common. LysoPC(16:0), in particular, consists of one chain of palmitic acid at the C-1 position. The palmitic acid moiety is derived from fish oils, milk fats, vegetable oils and animal fats. Lysophosphatidylcholine is found in small amounts in most tissues. It is formed by hydrolysis of phosphatidylcholine by the enzyme phospholipase A2, as part of the de-acylation/re-acylation cycle that controls its overall molecular species composition. It can also be formed inadvertently during extraction of lipids from tissues if the phospholipase is activated by careless handling. In blood plasma significant amounts of lysophosphatidylcholine are formed by a specific enzyme system, lecithin:cholesterol acyltransferase (LCAT), which is secreted from the liver. The enzyme catalyzes the transfer of the fatty acids of position sn-2 of phosphatidylcholine to the free cholesterol in plasma, with formation of cholesterol esters and lysophosphatidylcholine. Lysophospholipids have a role in lipid signaling by acting on lysophospholipid receptors (LPL-R). LPL-Rs are members of the G protein-coupled receptor family of integral membrane proteins.
LysoPC(0:0/16:0)
C24H50NO7P (495.33247200000005)
LysoPC(0:0/16:0) is a lysophosphatidylcholine, which is a lysophospholipid. The term lysophospholipid (LPL) refers to any phospholipid that is missing one of its two O-acyl chains. Thus, LPLs have a free alcohol in either the sn-1 or sn-2 position. The prefix lyso- comes from the fact that lysophospholipids were originally found to be hemolytic however it is now used to refer generally to phospholipids missing an acyl chain. LPLs are usually the result of phospholipase A-type enzymatic activity on regular phospholipids such as phosphatidylcholine or phosphatidic acid, although they can also be generated by the acylation of glycerophospholipids or the phosphorylation of monoacylglycerols. Lysophosphatidylcholine is found in small amounts in most tissues. It is formed by hydrolysis of phosphatidylcholine by the enzyme phospholipase A2 as part of the de-acylation/re-acylation cycle that controls its overall molecular species composition. It can also be formed inadvertently during extraction of lipids from tissues if the phospholipase is activated by careless handling. There is also a phospholipase A1, which is able to cleave the sn-1 ester bond. Lysophosphatidylcholine has pro-inflammatory properties in vitro and it is known to be a pathological component of oxidized lipoproteins (LDL) in plasma and of atherosclerotic lesions. Recently, it has been found to have some functions in cell signalling, and specific receptors (coupled to G proteins) have been identified. It activates the specific phospholipase C that releases diacylglycerols and inositol triphosphate with resultant increases in intracellular Ca2+ and activation of protein kinase C. It also activates the mitogen-activated protein kinase in certain cell types. Lysophosphatidylcholines can have different combinations of fatty acids of varying lengths and saturation attached at the C-1 (sn-1) or C-2 (sn-2) position. LysoPC(0:0/16:0), in particular, consists of one chain of palmitic acid at the C-2 position.
(5Z)-7-[(1R,2R,3R,5S)-3,5-Dihydroxy-2-[(1E,3S,5Z)-3-hydroxyocta-1,5-dien-1-yl]cyclopentyl]hept-5-enoylcarnitine
(5Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(1E,3S,5Z)-3-hydroxyocta-1,5-dien-1-yl]cyclopentyl]hept-5-enoylcarnitine is an acylcarnitine. More specifically, it is an (5Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(1E,3S,5Z)-3-hydroxyocta-1,5-dien-1-yl]cyclopentyl]hept-5-enoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (5Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(1E,3S,5Z)-3-hydroxyocta-1,5-dien-1-yl]cyclopentyl]hept-5-enoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine (5Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(1E,3S,5Z)-3-hydroxyocta-1,5-dien-1-yl]cyclopentyl]hept-5-enoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
Cholylserine
Cholylserine belongs to a class of molecules known as bile acid-amino acid conjugates. These are bile acid conjugates that consist of a primary bile acid such as cholic acid, doxycholic acid and chenodeoxycholic acid, conjugated to an amino acid. Cholylserine consists of the bile acid cholic acid conjugated to the amino acid Serine conjugated at the C24 acyl site.Bile acids play an important role in regulating various physiological systems, such as fat digestion, cholesterol metabolism, vitamin absorption, liver function, and enterohepatic circulation through their combined signaling, detergent, and antimicrobial mechanisms (PMID: 34127070). Bile acids also act as detergents in the gut and support the absorption of fats through the intestinal membrane. These same properties allow for the disruption of bacterial membranes, thereby allowing them to serve a bacteriocidal or bacteriostatic function. In humans (and other mammals) bile acids are normally conjugated with the amino acids glycine and taurine by the liver. This conjugation catalyzed by two liver enzymes, bile acid CoA ligase (BAL) and bile acid CoA: amino acid N-acyltransferase (BAT). Glycine and taurine bound BAs are also referred to as bile salts due to their decreased pKa and complete ionization resulting in these compounds being present as anions in vivo. Unlike glycine and taurine-conjugated bile acids, these recently discovered bile acids, such as Cholylserine, are produced by the gut microbiota, making them secondary bile acids (PMID: 32103176) or microbially conjugated bile acids (MCBAs) (PMID: 34127070). Evidence suggests that these bile acid-amino acid conjugates are produced by microbes belonging to Clostridia species (PMID: 32103176). These unusual bile acid-amino acid conjugates are found in higher frequency in patients with inflammatory bowel disease (IBD), cystic fibrosis (CF) and in infants (PMID: 32103176). Cholylserine appears to act as an agonist for the farnesoid X receptor (FXR) and it can also lead to reduced expression of bile acid synthesis genes (PMID: 32103176). It currently appears that microbially conjugated bile acids (MCBAs) or amino acid-bile acid conjugates are only conjugated to cholic acid, deoxycholic acid and chenodeoxycholic acid (PMID: 34127070). It has been estimated that if microbial conjugation of bile acids is very promiscuous and occurs for all potential oxidized, epimerized, and dehydroxylated states of each hydroxyl group present on cholic acid (C3, C7, C12) in addition to ring orientation, the total number of potential human bile acid conjugates could be over 2800 (PMID: 34127070).
Chenodeoxycholylcysteine
C27H45NO5S (495.30182800000006)
Deoxycholylcysteine
C27H45NO5S (495.30182800000006)
1-Nonadecanoyl-glycero-3-phosphoethanolamine
C24H50NO7P (495.33247200000005)
N(4)-Octadecyl-1-arabinofuranosylcytosine
C27H49N3O5 (495.36720240000005)
Mibefradil
1-Palmitoylphosphatidylcholine
C24H50NO7P (495.33247200000005)
Sabine
20-Ethyl-1,7,8-trihydroxy-6,16-dimethoxy-4-(methoxymethyl)aconitan-14-yl acetate #
C26H41NO8 (495.28320260000004)
6-O-Acetyl-14-O-methyldelphinifoline
C26H41NO8 (495.28320260000004)
1-O-hexadecyl-2-C-methyl-3-phosphatidylcholine
C25H54NO6P (495.36885540000003)
Acquisition and generation of the data is financially supported by the Max-Planck-Society
(1alpha,6beta,14alpha,16beta)-4-[(acetyloxy)methyl]-20-ethyl-6,14,16-trimethoxyaconitane-1,7,8-triol|1-O-demethyltricornine
C26H41NO8 (495.28320260000004)
cyclo (-Gly-L-Orn-L-Ile-3-amino-10-methyldodecanoyl-)|rhodopeptin C2
C26H49N5O4 (495.37843540000006)
5beta-Cevan-3beta,4alpha,12,14,16beta,17,20-heptaol|5beta-cevane-3beta,4alpha,12,14,16beta,17,20-heptaol
dysoxyhainanin A
C31H45NO4 (495.33484100000004)
A pentacyclic triterpenoid with a rearranged oleanane skeleton isolated from the whole plants of Dysoxylum hainanense. It exhibits antibacterial activity against Gram-positive bacteria.
cyclo (-GlyL-Orn-L-Val-3-amino-12-methyltridecanoyl-)|rhodopeptin C3
C26H49N5O4 (495.37843540000006)
1-O-Hexadecyl-2-O-methyl-rac-glycero-3-phosphocholine
C25H54NO6P (495.36885540000003)
PC(16:0/0:0)
C24H50NO7P (495.33247200000005)
CONFIDENCE standard compound; INTERNAL_ID 121 COVID info from WikiPathways Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS
Lysophosphatidylcholines, egg
C24H50NO7P (495.33247200000005)
LPC 16:0
C24H50NO7P (495.33247200000005)
Annotation level-2
Cysteine conjugated chenodeoxycholic acid
C27H45NO5S (495.30182800000006)
((4R)-4-((3R,5S,7R,10S,13R,14S)-3,7-dihydroxy-10,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)pentanoyl)cysteine
C27H45NO5S (495.30182800000006)
1-Palmitoyl-sn-glycero-3-phosphocholine
C24H50NO7P (495.33247200000005)
LysoPhosphatidylcholine_16_0
C24H50NO7P (495.33247200000005)
Ala His Ile Arg
Ala His Leu Arg
Ala His Arg Ile
Ala His Arg Leu
Ala Ile His Arg
Ala Ile Arg His
Ala Leu His Arg
Ala Leu Arg His
Ala Arg His Ile
Ala Arg His Leu
Ala Arg Ile His
Ala Arg Leu His
His Ala Ile Arg
His Ala Leu Arg
His Ala Arg Ile
His Ala Arg Leu
His Ile Ala Arg
His Ile Lys Val
C23H41N7O5 (495.31690160000005)
His Ile Arg Ala
His Ile Val Lys
C23H41N7O5 (495.31690160000005)
His Lys Ile Val
C23H41N7O5 (495.31690160000005)
His Lys Leu Val
C23H41N7O5 (495.31690160000005)
His Lys Val Ile
C23H41N7O5 (495.31690160000005)
His Lys Val Leu
C23H41N7O5 (495.31690160000005)
His Leu Ala Arg
His Leu Lys Val
C23H41N7O5 (495.31690160000005)
His Leu Arg Ala
His Leu Val Lys
C23H41N7O5 (495.31690160000005)
His Arg Ala Ile
His Arg Ala Leu
His Arg Ile Ala
His Arg Leu Ala
His Val Ile Lys
C23H41N7O5 (495.31690160000005)
His Val Lys Ile
C23H41N7O5 (495.31690160000005)
His Val Lys Leu
C23H41N7O5 (495.31690160000005)
His Val Leu Lys
C23H41N7O5 (495.31690160000005)
Ile Ala His Arg
Ile Ala Arg His
Ile His Ala Arg
Ile His Lys Val
C23H41N7O5 (495.31690160000005)
Ile His Arg Ala
Ile His Val Lys
C23H41N7O5 (495.31690160000005)
Ile Lys His Val
C23H41N7O5 (495.31690160000005)
Ile Lys Val His
C23H41N7O5 (495.31690160000005)
Ile Arg Ala His
Ile Arg His Ala
Ile Val His Lys
C23H41N7O5 (495.31690160000005)
Ile Val Lys His
C23H41N7O5 (495.31690160000005)
Lys His Ile Val
C23H41N7O5 (495.31690160000005)
Lys His Leu Val
C23H41N7O5 (495.31690160000005)
Lys His Val Ile
C23H41N7O5 (495.31690160000005)
Lys His Val Leu
C23H41N7O5 (495.31690160000005)
Lys Ile His Val
C23H41N7O5 (495.31690160000005)
Lys Ile Val His
C23H41N7O5 (495.31690160000005)
Lys Leu His Val
C23H41N7O5 (495.31690160000005)
Lys Leu Val His
C23H41N7O5 (495.31690160000005)
Lys Val His Ile
C23H41N7O5 (495.31690160000005)
Lys Val His Leu
C23H41N7O5 (495.31690160000005)
Lys Val Ile His
C23H41N7O5 (495.31690160000005)
Lys Val Leu His
C23H41N7O5 (495.31690160000005)
Leu Ala His Arg
Leu Ala Arg His
Leu His Ala Arg
Leu His Lys Val
C23H41N7O5 (495.31690160000005)
Leu His Arg Ala
Leu His Val Lys
C23H41N7O5 (495.31690160000005)
Leu Lys His Val
C23H41N7O5 (495.31690160000005)
Leu Lys Val His
C23H41N7O5 (495.31690160000005)
Leu Arg Ala His
Leu Arg His Ala
1-Palmitoyllysophosphatidylcholine
C24H50NO7P (495.33247200000005)
Leu Val His Lys
C23H41N7O5 (495.31690160000005)
Leu Val Lys His
C23H41N7O5 (495.31690160000005)
Arg Ala His Ile
Arg Ala His Leu
Arg Ala Ile His
Arg Ala Leu His
Arg His Ala Ile
Arg His Ala Leu
Arg His Ile Ala
Arg His Leu Ala
Arg Ile Ala His
Arg Ile His Ala
Arg Leu Ala His
Arg Leu His Ala
Val His Ile Lys
C23H41N7O5 (495.31690160000005)
Val His Lys Ile
C23H41N7O5 (495.31690160000005)
Val His Lys Leu
C23H41N7O5 (495.31690160000005)
Val His Leu Lys
C23H41N7O5 (495.31690160000005)
Val Ile His Lys
C23H41N7O5 (495.31690160000005)
Val Ile Lys His
C23H41N7O5 (495.31690160000005)
Val Lys His Ile
C23H41N7O5 (495.31690160000005)
Val Lys His Leu
C23H41N7O5 (495.31690160000005)
Val Lys Ile His
C23H41N7O5 (495.31690160000005)
Val Lys Leu His
C23H41N7O5 (495.31690160000005)
Val Leu His Lys
C23H41N7O5 (495.31690160000005)
Val Leu Lys His
C23H41N7O5 (495.31690160000005)
PC(7:0/8:0)[U]
PC(8:0/7:0)[U]
Platelet-activating factor
C24H50NO7P (495.33247200000005)
PC(O-1:0/O-16:0)[U]
C25H54NO6P (495.36885540000003)
PC(O-16:0/O-1:0)
C25H54NO6P (495.36885540000003)
PC(O-16:0/O-1:0)[S]
C25H54NO6P (495.36885540000003)
ET 16OME
C25H54NO6P (495.36885540000003)
16:0 LYSO-PC
C24H50NO7P (495.33247200000005)
PC(16:0/0:0)[S]
C24H50NO7P (495.33247200000005)
PC(16:0/0:0)[U]
C24H50NO7P (495.33247200000005)
PC(0:0/16:0)
C24H50NO7P (495.33247200000005)
Palmi
C24H50NO7P (495.33247200000005)
PC(O-17:0/0:0)
C25H54NO6P (495.36885540000003)
2-O-methyl PAF C-16
C25H54NO6P (495.36885540000003)
LPE O-19:1;O
C24H50NO7P (495.33247200000005)
buta-1,3-diene,2-ethylhexyl prop-2-enoate,methyl 2-methylprop-2-enoate,prop-2-enenitrile,styrene
C31H45NO4 (495.33484100000004)
Treprostinil diolamine
C78274 - Agent Affecting Cardiovascular System > C29707 - Vasodilating Agent D002317 - Cardiovascular Agents > D000959 - Antihypertensive Agents C78568 - Prostaglandin Analogue
(3-Hexadecoxy-2-hydroxy-2-methylpropyl) 2-(trimethylazaniumyl)ethyl phosphate
C25H54NO6P (495.36885540000003)
(5Z)-7-[(1R,2R,3R,5S)-3,5-Dihydroxy-2-[(1E,3S,5Z)-3-hydroxyocta-1,5-dien-1-yl]cyclopentyl]hept-5-enoylcarnitine
8-[3-(Diethylamino)-1-(4-methoxyphenyl)propyl]-5,7-dimethoxy-4-pentyl-1-benzopyran-2-one
C30H41NO5 (495.29845760000006)
3alpha,20alpha-dihydroxy-5beta-pregnane 3-O-(beta-D-glucuronate)
1-[[(10S,11S)-13-[(2R)-1-hydroxypropan-2-yl]-11-methyl-14-oxo-9-oxa-13-azatricyclo[13.4.0.02,7]nonadeca-1(19),2,4,6,15,17-hexaen-10-yl]methyl]-1-methyl-3-[(2R)-3-methylbutan-2-yl]urea
C29H41N3O4 (495.30969060000007)
1-[[(10S,11R)-13-[(2S)-1-hydroxypropan-2-yl]-11-methyl-14-oxo-9-oxa-13-azatricyclo[13.4.0.02,7]nonadeca-1(19),2,4,6,15,17-hexaen-10-yl]methyl]-1-methyl-3-[(2R)-3-methylbutan-2-yl]urea
C29H41N3O4 (495.30969060000007)
1-[[(10S,11S)-13-[(2S)-1-hydroxypropan-2-yl]-11-methyl-14-oxo-9-oxa-13-azatricyclo[13.4.0.02,7]nonadeca-1(19),2,4,6,15,17-hexaen-10-yl]methyl]-1-methyl-3-[(2R)-3-methylbutan-2-yl]urea
C29H41N3O4 (495.30969060000007)
1-[[(10S,11R)-13-[(2R)-1-hydroxypropan-2-yl]-11-methyl-14-oxo-9-oxa-13-azatricyclo[13.4.0.02,7]nonadeca-1(19),2,4,6,15,17-hexaen-10-yl]methyl]-1-methyl-3-[(2S)-3-methylbutan-2-yl]urea
C29H41N3O4 (495.30969060000007)
(2S,3S,3aR,9bR)-3-(hydroxymethyl)-N-[3-(4-morpholinyl)propyl]-6-oxo-1-propyl-7-pyridin-4-yl-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide
C27H37N5O4 (495.28454020000004)
1-[[(10R,11S)-13-[(2S)-1-hydroxypropan-2-yl]-11-methyl-14-oxo-9-oxa-13-azatricyclo[13.4.0.02,7]nonadeca-1(19),2,4,6,15,17-hexaen-10-yl]methyl]-1-methyl-3-[(2R)-3-methylbutan-2-yl]urea
C29H41N3O4 (495.30969060000007)
1-[[(10R,11R)-13-[(2S)-1-hydroxypropan-2-yl]-11-methyl-14-oxo-9-oxa-13-azatricyclo[13.4.0.02,7]nonadeca-1(19),2,4,6,15,17-hexaen-10-yl]methyl]-1-methyl-3-[(2R)-3-methylbutan-2-yl]urea
C29H41N3O4 (495.30969060000007)
N-[(4R,7R,8R)-8-methoxy-4,7,10-trimethyl-11-oxo-5-(2-phenylethyl)-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]butanamide
C29H41N3O4 (495.30969060000007)
N-[(4S,7S,8R)-8-methoxy-4,7,10-trimethyl-11-oxo-5-(2-phenylethyl)-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]butanamide
C29H41N3O4 (495.30969060000007)
N-[(4S,7R,8S)-8-methoxy-4,7,10-trimethyl-11-oxo-5-(2-phenylethyl)-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]butanamide
C29H41N3O4 (495.30969060000007)
1-[[(10R,11S)-13-[(2R)-1-hydroxypropan-2-yl]-11-methyl-14-oxo-9-oxa-13-azatricyclo[13.4.0.02,7]nonadeca-1(19),2,4,6,15,17-hexaen-10-yl]methyl]-1-methyl-3-[(2R)-3-methylbutan-2-yl]urea
C29H41N3O4 (495.30969060000007)
1-[[(10R,11R)-13-[(2R)-1-hydroxypropan-2-yl]-11-methyl-14-oxo-9-oxa-13-azatricyclo[13.4.0.02,7]nonadeca-1(19),2,4,6,15,17-hexaen-10-yl]methyl]-1-methyl-3-[(2R)-3-methylbutan-2-yl]urea
C29H41N3O4 (495.30969060000007)
1-[[(10R,11R)-13-[(2R)-1-hydroxypropan-2-yl]-11-methyl-14-oxo-9-oxa-13-azatricyclo[13.4.0.02,7]nonadeca-1(19),2,4,6,15,17-hexaen-10-yl]methyl]-1-methyl-3-[(2S)-3-methylbutan-2-yl]urea
C29H41N3O4 (495.30969060000007)
N-[(4R,7R,8S)-8-methoxy-4,7,10-trimethyl-11-oxo-5-(2-phenylethyl)-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]butanamide
C29H41N3O4 (495.30969060000007)
N-[(4S,7S,8S)-8-methoxy-4,7,10-trimethyl-11-oxo-5-(2-phenylethyl)-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]butanamide
C29H41N3O4 (495.30969060000007)
N-[(4S,7R,8R)-8-methoxy-4,7,10-trimethyl-11-oxo-5-(2-phenylethyl)-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]butanamide
C29H41N3O4 (495.30969060000007)
N-[(4R,7S,8S)-8-methoxy-4,7,10-trimethyl-11-oxo-5-(2-phenylethyl)-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]butanamide
C29H41N3O4 (495.30969060000007)
N-[(4R,7S,8R)-8-methoxy-4,7,10-trimethyl-11-oxo-5-(2-phenylethyl)-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]butanamide
C29H41N3O4 (495.30969060000007)
1-[[(10S,11S)-13-[(2R)-1-hydroxypropan-2-yl]-11-methyl-14-oxo-9-oxa-13-azatricyclo[13.4.0.02,7]nonadeca-1(19),2,4,6,15,17-hexaen-10-yl]methyl]-1-methyl-3-[(2S)-3-methylbutan-2-yl]urea
C29H41N3O4 (495.30969060000007)
1-[[(10S,11S)-13-[(2S)-1-hydroxypropan-2-yl]-11-methyl-14-oxo-9-oxa-13-azatricyclo[13.4.0.02,7]nonadeca-1(19),2,4,6,15,17-hexaen-10-yl]methyl]-1-methyl-3-[(2S)-3-methylbutan-2-yl]urea
C29H41N3O4 (495.30969060000007)
1-[[(10R,11S)-13-[(2R)-1-hydroxypropan-2-yl]-11-methyl-14-oxo-9-oxa-13-azatricyclo[13.4.0.02,7]nonadeca-1(19),2,4,6,15,17-hexaen-10-yl]methyl]-1-methyl-3-[(2S)-3-methylbutan-2-yl]urea
C29H41N3O4 (495.30969060000007)
(2R,3R,3aS,9bS)-3-(hydroxymethyl)-N-[3-(4-morpholinyl)propyl]-6-oxo-1-propyl-7-pyridin-4-yl-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide
C27H37N5O4 (495.28454020000004)
1-[[(10R,11R)-13-[(2S)-1-hydroxypropan-2-yl]-11-methyl-14-oxo-9-oxa-13-azatricyclo[13.4.0.02,7]nonadeca-1(19),2,4,6,15,17-hexaen-10-yl]methyl]-1-methyl-3-[(2S)-3-methylbutan-2-yl]urea
C29H41N3O4 (495.30969060000007)
1-[[(10R,11S)-13-[(2S)-1-hydroxypropan-2-yl]-11-methyl-14-oxo-9-oxa-13-azatricyclo[13.4.0.02,7]nonadeca-1(19),2,4,6,15,17-hexaen-10-yl]methyl]-1-methyl-3-[(2S)-3-methylbutan-2-yl]urea
C29H41N3O4 (495.30969060000007)
N-hexanoylphytosphingosine 1-phosphate
C24H50NO7P (495.33247200000005)
(2-Octanoyloxy-3-octoxypropyl) 2-(trimethylazaniumyl)ethyl phosphate
C24H50NO7P (495.33247200000005)
[(2S)-2-hexadecanoyloxy-3-hydroxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
C24H50NO7P (495.33247200000005)
[1-Acetyloxy-3-[2-aminoethoxy(hydroxy)phosphoryl]oxypropan-2-yl] hexadecanoate
[1-[2-Aminoethoxy(hydroxy)phosphoryl]oxy-3-hexadecoxypropan-2-yl] propanoate
C24H50NO7P (495.33247200000005)
1-o-Heptadecyl-2-hydroxy-sn-glycero-3-phosphocholine
C25H54NO6P (495.36885540000003)
2-Aminoethyl (2-hydroxy-3-icosoxypropyl) hydrogen phosphate
C25H54NO6P (495.36885540000003)
(3Z,6Z,9Z,12Z,15Z)-N-[(4E,8E,12E)-1,3-dihydroxytetradeca-4,8,12-trien-2-yl]octadeca-3,6,9,12,15-pentaenamide
(2-Heptanoyloxy-3-nonoxypropyl) 2-(trimethylazaniumyl)ethyl phosphate
C24H50NO7P (495.33247200000005)
[1-[2-Aminoethoxy(hydroxy)phosphoryl]oxy-3-undecoxypropan-2-yl] octanoate
C24H50NO7P (495.33247200000005)
[1-[2-Aminoethoxy(hydroxy)phosphoryl]oxy-3-nonoxypropan-2-yl] decanoate
C24H50NO7P (495.33247200000005)
[1-[2-Aminoethoxy(hydroxy)phosphoryl]oxy-3-tridecoxypropan-2-yl] hexanoate
C24H50NO7P (495.33247200000005)
[1-[2-Aminoethoxy(hydroxy)phosphoryl]oxy-3-decoxypropan-2-yl] nonanoate
C24H50NO7P (495.33247200000005)
[1-[2-Aminoethoxy(hydroxy)phosphoryl]oxy-3-dodecoxypropan-2-yl] heptanoate
C24H50NO7P (495.33247200000005)
[1-[2-Aminoethoxy(hydroxy)phosphoryl]oxy-3-octoxypropan-2-yl] undecanoate
C24H50NO7P (495.33247200000005)
[1-[2-Aminoethoxy(hydroxy)phosphoryl]oxy-3-heptadecoxypropan-2-yl] acetate
C24H50NO7P (495.33247200000005)
[1-[2-Aminoethoxy(hydroxy)phosphoryl]oxy-3-pentadecoxypropan-2-yl] butanoate
C24H50NO7P (495.33247200000005)
(3-Decoxy-2-hexanoyloxypropyl) 2-(trimethylazaniumyl)ethyl phosphate
C24H50NO7P (495.33247200000005)
(2-Butanoyloxy-3-dodecoxypropyl) 2-(trimethylazaniumyl)ethyl phosphate
C24H50NO7P (495.33247200000005)
(2-Propanoyloxy-3-tridecoxypropyl) 2-(trimethylazaniumyl)ethyl phosphate
C24H50NO7P (495.33247200000005)
(2-Pentanoyloxy-3-undecoxypropyl) 2-(trimethylazaniumyl)ethyl phosphate
C24H50NO7P (495.33247200000005)
(E)-2-[[(4Z,7Z,10Z,13Z)-hexadeca-4,7,10,13-tetraenoyl]amino]-3-hydroxyundec-4-ene-1-sulfonic acid
C27H45NO5S (495.30182800000006)
(2-Acetyloxy-3-tetradecoxypropyl) 2-(trimethylazaniumyl)ethyl phosphate
C24H50NO7P (495.33247200000005)
[1-[2-Aminoethoxy(hydroxy)phosphoryl]oxy-3-tetradecoxypropan-2-yl] pentanoate
C24H50NO7P (495.33247200000005)
[3-[2-Aminoethoxy(hydroxy)phosphoryl]oxy-2-nonanoyloxypropyl] nonanoate
(E)-(3R)-(1R,2S,5R)-8-Phenylmenthyl 3-benzylamino-5-phenyl-4-pentenoate
C34H41NO2 (495.31371260000003)
(3-Heptanoyloxy-2-octanoyloxypropyl) 2-(trimethylazaniumyl)ethyl phosphate
[1-[2-Aminoethoxy(hydroxy)phosphoryl]oxy-3-propanoyloxypropan-2-yl] pentadecanoate
[1-[2-Aminoethoxy(hydroxy)phosphoryl]oxy-3-pentanoyloxypropan-2-yl] tridecanoate
(2-Dodecanoyloxy-3-propanoyloxypropyl) 2-(trimethylazaniumyl)ethyl phosphate
[1-[2-Aminoethoxy(hydroxy)phosphoryl]oxy-3-hexanoyloxypropan-2-yl] dodecanoate
(3-Acetyloxy-2-tridecanoyloxypropyl) 2-(trimethylazaniumyl)ethyl phosphate
[1-[2-Aminoethoxy(hydroxy)phosphoryl]oxy-3-heptanoyloxypropan-2-yl] undecanoate
[1-[2-Aminoethoxy(hydroxy)phosphoryl]oxy-3-butanoyloxypropan-2-yl] tetradecanoate
(3-Hexanoyloxy-2-nonanoyloxypropyl) 2-(trimethylazaniumyl)ethyl phosphate
(2-Decanoyloxy-3-pentanoyloxypropyl) 2-(trimethylazaniumyl)ethyl phosphate
[1-[2-Aminoethoxy(hydroxy)phosphoryl]oxy-3-octanoyloxypropan-2-yl] decanoate
(3-Butanoyloxy-2-undecanoyloxypropyl) 2-(trimethylazaniumyl)ethyl phosphate
2-[Hydroxy-[3-hydroxy-2-(nonanoylamino)decoxy]phosphoryl]oxyethyl-trimethylazanium
2-[Hydroxy-[3-hydroxy-2-(propanoylamino)hexadecoxy]phosphoryl]oxyethyl-trimethylazanium
2-[(2-Acetamido-3-hydroxyheptadecoxy)-hydroxyphosphoryl]oxyethyl-trimethylazanium
2-[Hydroxy-[3-hydroxy-2-(octanoylamino)undecoxy]phosphoryl]oxyethyl-trimethylazanium
2-[[2-(Hexanoylamino)-3-hydroxytridecoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
2-[[2-(Butanoylamino)-3-hydroxypentadecoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
2-[Hydroxy-[3-hydroxy-2-(pentanoylamino)tetradecoxy]phosphoryl]oxyethyl-trimethylazanium
2-[[2-(Heptanoylamino)-3-hydroxydodecoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
2-[Hydroxy-[3-hydroxy-2-(undecanoylamino)octoxy]phosphoryl]oxyethyl-trimethylazanium
2-[[2-(Decanoylamino)-3-hydroxynonoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
Antibiotic JI-20B
C20H41N5O9 (495.2904136000001)
D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D005839 - Gentamicins
N(2)-acetylgentamycin C1a(4+)
Tetracation of N(2)-acetylgentamycin C1a.
2-Palmitoyl-sn-glycero-3-phosphocholine
C24H50NO7P (495.33247200000005)
A lysophosphatidylcholine 16:0 in which the acyl group is specified as palmitoyl (hexadecanoyl) and is located at position 2.
2-methoxyacetic acid [2-[2-[3-(1H-benzimidazol-2-yl)propyl-methylamino]ethyl]-6-fluoro-1-propan-2-yl-3,4-dihydro-1H-naphthalen-2-yl] ester
1-tetradecyl-2-acetyl-sn-glycero-3-phosphocholine
C24H50NO7P (495.33247200000005)
A 2-acetyl-1-alkyl-sn-glycero-3-phosphocholine in which the alkyl group is specified as tetradecyl.
1-heptadecyl-sn-glycero-3-phosphocholine
C25H54NO6P (495.36885540000003)
1-eicosyl-glycero-3-phosphoethanolamine
C25H54NO6P (495.36885540000003)
1-nonadecanoyl-glycero-3-phosphoethanolamine
C24H50NO7P (495.33247200000005)
1-(2-methoxy-6Z-octadecenyl)-sn-glycero-3-phosphoethanolamine
C24H50NO7P (495.33247200000005)
phosphatidylethanolamine 18:0 zwitterion
A 1,2-diacyl-sn-glycero-3-phosphoethanolamine zwitterion in which the two acyl groups contain a total of 18 carbons and no double bonds.
phosphatidylcholine 15:0
A 1,2-diacyl-sn-glycero-3-phosphocholine in which the two acyl groups contain a total of 15 carbons and no double bonds.
lysophosphatidylcholine 16:0
C24H50NO7P (495.33247200000005)
A lysophosphatidylcholine in which the acyl group has a fully saturated C16 chain and is attached to the glycero moiety at either position 1 or 2.
Lysophosphatidylcholine(0:0/16:0)
C24H50NO7P (495.33247200000005)
A 2-acyl-sn-glycero-3-phosphocholine in which the 2-acyl group contains 16 carbons and is fully saturated.
1-hexadecanoyl-sn-glycero-3-phosphocholine
C24H50NO7P (495.33247200000005)
A lysophosphatidylcholine 16:0 in which a hexadecanoyl (palmitoyl) group is attached to the glycero moiety at position 1.
PC(15:0)
Provides by LipidSearch Vendor. © Copyright 2006-2024 Thermo Fisher Scientific Inc. All rights reserved
LdMePE(17:0)
C24H50NO7P (495.33247200000005)
Provides by LipidSearch Vendor. © Copyright 2006-2024 Thermo Fisher Scientific Inc. All rights reserved
LdMePE(18:0)
C25H54NO6P (495.36885540000003)
Provides by LipidSearch Vendor. © Copyright 2006-2024 Thermo Fisher Scientific Inc. All rights reserved
PE(19:0)
C24H50NO7P (495.33247200000005)
Provides by LipidSearch Vendor. © Copyright 2006-2024 Thermo Fisher Scientific Inc. All rights reserved
2-{[(1-{[(3z)-2,7-dihydroxy-5-isopropyl-1,6-diazacyclododeca-1,3,6-trien-8-yl]-c-hydroxycarbonimidoyl}-2-methylpropyl)-c-hydroxycarbonimidoyl]amino}-3-methylbutanoic acid
C24H41N5O6 (495.30566860000005)
(1r,3s,4r,9r,10r,12s,13r,14s,17s,19s,21r)-3,6,10,13,14,19-hexamethyl-24,27-dioxa-23-azaheptacyclo[11.10.3.1¹⁷,²¹.0¹,¹⁴.0³,¹².0⁴,⁹.0¹⁷,²³]heptacos-6-ene-8,11,25-trione
C30H41NO5 (495.29845760000006)
11-ethyl-8,9,16-trihydroxy-4,6-dimethoxy-13-(methoxymethyl)-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecan-18-yl acetate
C26H41NO8 (495.28320260000004)
11-ethyl-8-hydroxy-4,6-dimethoxy-13-methyl-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecan-16-yl benzoate
C30H41NO5 (495.29845760000006)
6-(3-aminopropyl)-13-(7-methylnonyl)-3-(sec-butyl)-1,4,7,10-tetraazacyclotrideca-1,4,7,10-tetraene-2,5,8,11-tetrol
C26H49N5O4 (495.37843540000006)
aconitum kirinense alkaloid
C26H41NO8 (495.28320260000004)
{"Ingredient_id": "HBIN014585","Ingredient_name": "aconitum kirinense alkaloid","Alias": "NA","Ingredient_formula": "C26H41NO8","Ingredient_Smile": "NA","Ingredient_weight": "0","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "NA","TCMSP_id": "NA","TCM_ID_id": "7188","PubChem_id": "NA","DrugBank_id": "NA"}
(1r,2r,3r,4r,5r,6s,8r,9r,10r,13r,16s,17s,18s)-11-ethyl-8,9,16-trihydroxy-4,6-dimethoxy-13-(methoxymethyl)-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecan-18-yl acetate
C26H41NO8 (495.28320260000004)
(2-{[(2r)-3-(hexadecanoyloxy)-2-hydroxypropyl phosphonato]oxy}ethyl)trimethylazanium
C24H50NO7P (495.33247200000005)
{11-ethyl-8,9,16-trihydroxy-4,6,18-trimethoxy-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecan-13-yl}methyl acetate
C26H41NO8 (495.28320260000004)
(2s,3s)-2-{[(2s)-1-hydroxy-2-[(1-hydroxy-3-methylbutylidene)amino]-3-phenylpropylidene]amino}-n-[(2s)-1-hydroxy-3-phenylpropan-2-yl]-3-methylpentanimidic acid
C29H41N3O4 (495.30969060000007)
(1s,2r,3r,4s,5r,6s,8s,9s,10r,13s,16s,17r)-11-ethyl-8-hydroxy-4,6-dimethoxy-13-methyl-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecan-16-yl benzoate
C30H41NO5 (495.29845760000006)
[(1s,2r,3r,4s,5r,6s,8r,9s,10s,13s,16s,17r,18s)-11-ethyl-8,9,16-trihydroxy-4,6,18-trimethoxy-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecan-13-yl]methyl acetate
C26H41NO8 (495.28320260000004)
(1s,2r,3r,4s,5r,6s,8r,9r,10s,13s,16s,17r,18s)-11-ethyl-8,9,16-trihydroxy-4,6-dimethoxy-13-(methoxymethyl)-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecan-18-yl acetate
C26H41NO8 (495.28320260000004)
(3s,6s,13r)-6-(3-aminopropyl)-3-isopropyl-13-(9-methyldecyl)-1,4,7,10-tetraazacyclotrideca-1,4,7,10-tetraene-2,5,8,11-tetrol
C26H49N5O4 (495.37843540000006)
(1r,2r,3r,4r,5r,6r,8r,9r,10r,13r,16s,17s,18s)-11-ethyl-9,16,18-trihydroxy-6,8-dimethoxy-13-(methoxymethyl)-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecan-4-yl acetate
C26H41NO8 (495.28320260000004)
14-ethyl-4,6,19-trimethoxy-16-(methoxymethyl)-9,11-dioxa-14-azaheptacyclo[10.7.2.1²,⁵.0¹,¹³.0³,⁸.0⁸,¹².0¹⁶,²⁰]docosane-2,3-diol
C26H41NO8 (495.28320260000004)
2-({1-hydroxy-2-[(1-hydroxy-3-methylbutylidene)amino]-3-phenylpropylidene}amino)-n-(1-hydroxy-3-phenylpropan-2-yl)-3-methylpentanimidic acid
C29H41N3O4 (495.30969060000007)
(3s,6s)-6-(3-aminopropyl)-13-(7-methylnonyl)-3-(sec-butyl)-1,4,7,10-tetraazacyclotrideca-1,4,7,10-tetraene-2,5,8,11-tetrol
C26H49N5O4 (495.37843540000006)
(3as,4s,9bs)-4-{3-[n'-(3-methylbut-2-en-1-yl)carbamimidamido]propyl}-1-[n-(3-methylbut-2-en-1-yl)carbamimidoyl]-2h,3h,3ah,4h,5h,9bh-pyrrolo[3,2-c]quinoline-8-carboxylic acid
6-(3-aminopropyl)-3-isopropyl-13-(9-methyldecyl)-1,4,7,10-tetraazacyclotrideca-1,4,7,10-tetraene-2,5,8,11-tetrol
C26H49N5O4 (495.37843540000006)
11-ethyl-9,16,18-trihydroxy-6,8-dimethoxy-13-(methoxymethyl)-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecan-4-yl acetate
C26H41NO8 (495.28320260000004)
11-ethyl-8,9,16-trihydroxy-6,18-dimethoxy-13-(methoxymethyl)-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecan-4-yl acetate
C26H41NO8 (495.28320260000004)
(1s,2r,3r,4s,5r,6s,8r,9s,10r,13s,16s,17r,18s)-11-ethyl-8,9,16-trihydroxy-6,18-dimethoxy-13-(methoxymethyl)-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecan-4-yl acetate
C26H41NO8 (495.28320260000004)
(1s,2r,3r,4s,5r,6s,8r,9s,10s,13s,16s,17r,18r)-11-ethyl-9,16,18-trihydroxy-6,8-dimethoxy-13-(methoxymethyl)-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecan-4-yl acetate
C26H41NO8 (495.28320260000004)
(3s,6s)-6-(3-aminopropyl)-3-isopropyl-13-(9-methyldecyl)-1,4,7,10-tetraazacyclotrideca-1,4,7,10-tetraene-2,5,8,11-tetrol
C26H49N5O4 (495.37843540000006)
(1s,2r,3r,4r,5r,6s,8r,9s,10s,13s,16r,17r,18r)-11-ethyl-8,9,16-trihydroxy-6,18-dimethoxy-13-(methoxymethyl)-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecan-4-yl acetate
C26H41NO8 (495.28320260000004)
(3s,6s,13r)-6-(3-aminopropyl)-13-(7-methylnonyl)-3-(sec-butyl)-1,4,7,10-tetraazacyclotrideca-1,4,7,10-tetraene-2,5,8,11-tetrol
C26H49N5O4 (495.37843540000006)
2-[({1-[(2,7-dihydroxy-5-isopropyl-1,6-diazacyclododeca-1,3,6-trien-8-yl)-c-hydroxycarbonimidoyl]-2-methylpropyl}-c-hydroxycarbonimidoyl)amino]-3-methylbutanoic acid
C24H41N5O6 (495.30566860000005)
(1s,2r,3r,4s,5r,6s,8r,9s,10s,13s,16s,17r,18s)-11-ethyl-8,9,16-trihydroxy-6,18-dimethoxy-13-(methoxymethyl)-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecan-4-yl acetate
C26H41NO8 (495.28320260000004)
(2-{[(2r)-2-hydroxy-3-[(15-methylhexadecyl)oxy]propyl phosphonato]oxy}ethyl)trimethylazanium
C25H54NO6P (495.36885540000003)
(3s,6s,9r)-13-heptyl-5,8,11-trihydroxy-3-isopropyl-6,9-bis(2-methylpropyl)-1-oxa-4,7,10-triazacyclotrideca-4,7,10-trien-2-one
C27H49N3O5 (495.36720240000005)
[(1s,2r,3r,4s,5r,6s,8r,9r,10s,13s,16s,17r,18s)-11-ethyl-8,9,16-trihydroxy-4,6,18-trimethoxy-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecan-13-yl]methyl acetate
C26H41NO8 (495.28320260000004)